Repurposing Clinically Safe Drugs to Guide DNA Repair in CRISPR

Study Background and Research Question

DNA double-strand breaks (DSBs) are critical lesions that can arise both spontaneously, due to metabolic byproducts such as reactive oxygen species, and deliberately, as in CRISPR-Cas9 genome editing or cancer chemotherapy. The way cells repair these DSBs—principally via non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), or homology-directed repair (HDR)—determines the nature and fidelity of genome modifications. Modulating the balance between these pathways is of immense interest for disease modeling, gene therapy, immuno-oncology, and precision medicine. However, small-molecule tools for reliably shifting this balance in clinically relevant cells have remained limited. The study by Macak, Kanis, and Riesenberg addresses whether existing, clinically safe drugs can be repurposed to influence DNA repair pathway choice, thus expanding the toolkit for controlled genome editing and synthetic lethality strategies (reference study).

Key Innovation from the Reference Study

The central innovation of this work lies in the systematic, high-throughput screening of over 7,000 FDA-approved compounds for their capacity to modulate DSB repair outcomes in human induced pluripotent stem cells (hiPSCs) subjected to CRISPR-Cas9 editing. Unlike previous efforts focusing on a handful of targeted inhibitors, this approach enables broad identification of both enhancers and inhibitors of key repair pathways, including NHEJ, MMEJ, and HDR. The study further integrates functional genomics to reveal how specific drug targets—such as estrogen receptor 2 (ESR2) and aldehyde oxidase 1 (AOX1)—intersect with core DNA repair proteins, uncovering synergistic combinations that dramatically increase the frequency of precise HDR events. This work not only provides an unprecedented resource for precision genome editing but also highlights new routes for exploiting synthetic lethality in cancer cells with repair deficiencies.

Methods and Experimental Design Insights

The experimental workflow was meticulously designed to ensure both scale and specificity. The authors utilized a human iPSC line (409B2) engineered for doxycycline-inducible Cas9 expression (iCRISPR). Cells were treated with candidate drugs during genome editing at a defined locus (FRMD7), then allowed to recover in drug-free media. Cellular viability was assessed using a resazurin-based fluorescence assay, while DNA repair outcomes were quantified by Illumina sequencing of the edited locus. This allowed discrimination between precise HDR, small indels typical of NHEJ, and larger deletions associated with MMEJ. Each compound was screened in a single replicate, but the high throughput and deep sequencing provided robust statistical power for pathway assignment and hit calling (see experimental design).

Protocol Parameters

• Cell system: Human iPSC line (409B2) with inducible Cas9; target locus: FRMD7.
• Drug treatment: FDA-approved compounds (>7,000), tested at standardized concentrations alongside DMSO controls.
• Editing window: Drug exposure coincided with CRISPR-Cas9 activity for maximal pathway modulation.
• Outcome quantification: Post-recovery, cell viability measured by resazurin assay; repair events classified by Illumina sequencing.
• Pathway assignment: Sequencing reads mapped to NHEJ (<2 bp microhomology), MMEJ (≥2 bp microhomology), or HDR (precise edits using exogenous donor templates).

Core Findings and Why They Matter

The screen identified multiple clinically safe drugs capable of either enhancing or inhibiting specific DNA repair pathways. Notably, the study found that:

• Several drugs increased the proportion of HDR events, offering a route to more precise genome editing, critical for applications requiring single-nucleotide corrections or gene knock-in.
• Other compounds preferentially inhibited NHEJ or MMEJ, shifting the balance towards alternative, sometimes therapeutically desirable, repair outcomes.
• Silencing ESR2, especially when combined with pharmacological NHEJ inhibition, produced a synergistic ~4.6-fold increase in HDR frequency, suggesting combinatorial strategies can substantially enhance editing precision.
• Some drugs induced synthetic lethality in cells deficient for either NHEJ or HDR, opening opportunities to target cancer cells with specific repair defects while sparing healthy tissue.

These findings provide a powerful framework for drug-guided modulation of DNA repair, which can be leveraged in disease modeling, engineering of CAR-T cells, and the development of safer, more effective gene therapies (study details).

Comparison with Existing Internal Articles

The current study’s broad drug screening strategy extends and complements prior workflow-focused literature, particularly in the context of calcium signaling and DNA repair modulation. For example, internal articles such as “Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagonist Workflows” and “Dantrolene Sodium Salt: Precision Ryanodine Receptor Antagonist Workflows” discuss how targeted ryanodine receptor antagonists like dantrolene sodium salt can be used to modulate intracellular calcium homeostasis—an upstream regulator of DNA repair processes and cell fate decisions. These resources offer actionable protocols and troubleshooting advice for integrating ryanodine receptor antagonists into studies of DNA repair and genome editing. While the reference paper focuses on broad drug repurposing for pathway choice, these internal articles provide detailed workflow guidance for researchers targeting calcium-dependent signaling in DNA repair and disease modeling. The synergy between pharmacological pathway modulation and precise workflow execution is a recurring theme across both domains.

Limitations and Transferability

Despite its scale and rigor, the study is subject to several limitations:

• Drug effects were measured in a single human iPSC line and at one genomic locus, which may not capture all cell type- or locus-specific nuances.
• Most compounds were tested at a single concentration, so dose-dependent effects or cytotoxicity thresholds may require further optimization.
• Functional validation was performed for a subset of hits; some pathway assignments may benefit from orthogonal assays or broader biological readouts.
• The potential for off-target activities or pleiotropic effects, especially among drugs with multiple known targets, cannot be fully excluded.

Transferability to other cellular contexts (e.g., primary cells, disease models, or different editing platforms) will require additional optimization and validation. However, the core principle—that clinically safe drugs can be rationally repurposed to steer DNA repair pathway choice—is robust and broadly applicable (related discussion).

Why this cross-domain matters, maturity, and limitations

Bridging pharmacological DNA repair modulation with advanced genome editing workflows has substantial translational value. Compounds that influence calcium signaling, such as ryanodine receptor antagonists, intersect with DNA repair not just at the signaling level but also at the level of cell survival and stress responses. However, while cross-domain strategies hold promise, their maturity varies: most evidence supporting direct integration comes from in vitro models or controlled experimental settings. In vivo applications and clinical translation will require rigorous, context-specific validation to address cell-type specificity, pharmacokinetics, and safety profiles.

Research Support Resources

Researchers interested in modulating calcium-dependent signaling during DNA repair studies can utilize Dantrolene, sodium salt (SKU B6329), a potent ryanodine receptor antagonist with documented specificity for RyR2-mediated calcium release. This compound is well-suited for translational workflows requiring precise intracellular calcium modulation, as described in both the internal workflow guides and the product information. For optimal use, researchers should consider solubility and stability recommendations, and further tailor protocols for their specific cell systems and DNA repair endpoints.